Loading company details...
Beta
Latest Form 4 (Sep 30, 2026): Erez Chimovits (Director): Conversion of 7,127,019 shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Erez Chimovits | Conversion | 7,127,019 | n/a |
| Sep 30, 2026 | Carl L. Gordon | Conversion | 10,690,530 | n/a |
| Sep 30, 2026 | ORBIMED ADVISORS LLC | Conversion | 10,690,530 | n/a |
| Sep 30, 2026 | SR ONE CAPITAL MANAGEMENT, LLC | Conversion | 3,334,938 | n/a |
| Sep 30, 2026 | Simeon George | Conversion | 3,334,938 | n/a |
| Sep 30, 2026 | LAV Biosciences Fund V, L.P. | Conversion | 8,908,775 | n/a |
| Sep 28, 2026 | Rui (nmn) Zhu, Chief Technology Officer | Grant/Award | 512,076 | n/a |
| Sep 28, 2026 | Alan Robert MacLeod, Chief Scientific Officer | Grant/Award | 170,692 | n/a |
| Sep 28, 2026 | Ryan Fisk, CFO and CBO | Grant/Award | 170,692 | n/a |
| Sep 28, 2026 | Zhen Li, President and CEO | Grant/Award | 1,024,152 | n/a |